Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMASTRE: sacubitril/valsartan for primary prevention of cardiotoxicity during systemic breast cancer treatment
2022-003046-13Phase 3Active
- Sponsor
- Silesian Center for Heart Diseases
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cardiotoxicity comparing Entresto prophylaxis with Placebo (2 arms). Primary endpoint: Decrease in left ventricular ejection fraction of at least 5%. Started Sep 2024; status: active.
02
Drugs
sacubitril + valsartan
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on 2022-003046-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003046-13.